RS20050084A - Vegfr-2 and vegfr-3 inhibitory anthranylamidopyrydines - Google Patents
Vegfr-2 and vegfr-3 inhibitory anthranylamidopyrydinesInfo
- Publication number
- RS20050084A RS20050084A YUP-2005/0084A YUP20050084A RS20050084A RS 20050084 A RS20050084 A RS 20050084A YU P20050084 A YUP20050084 A YU P20050084A RS 20050084 A RS20050084 A RS 20050084A
- Authority
- RS
- Serbia
- Prior art keywords
- vegfr
- compounds
- diseases
- disease
- production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said compounds can be used, for example, in tumour or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as for example, stent-induced restenoses, endometriosis, Crohn's disease, Hodgkin's disease, leukaemia, arthritis, such as rheumatoid arthritis, haemangioma, angiofibroma, eye disease, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejection and glomerulopathy, fibrotic diseases, such as liver cirrhosis, mesangial cell proliferative diseases, artherosclerosis, injuries to nervous tissue and inhibition of the reocclusion of vessels after balloon catheter treatment, in vessel prosthetics, or after the application of mechanical devices to hold open vessels, such as for example, stents, as immune suppressants, as a support for scar-free wound healing, age spots and contact dermatitis. Said compounds may also be used as VEGFR-3 inhibitors in lymphangiogenesis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10235690A DE10235690A1 (en) | 2002-07-31 | 2002-07-31 | New N-benzyl-anthranilic acid (hetero)arylamide derivatives and analogs, are tyrosine kinase KDR and FLT inhibitors and angiogenesis inhibitors, useful e.g. for treating tumors, psoriasis or restenosis |
DE10328036A DE10328036A1 (en) | 2003-06-19 | 2003-06-19 | New N-benzyl-anthranilic acid (hetero)arylamide derivatives and analogs, are tyrosine kinase KDR and FLT inhibitors and angiogenesis inhibitors, useful e.g. for treating tumors, psoriasis or restenosis |
PCT/EP2003/007964 WO2004013102A1 (en) | 2002-07-31 | 2003-07-22 | Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines |
Publications (1)
Publication Number | Publication Date |
---|---|
RS20050084A true RS20050084A (en) | 2007-09-21 |
Family
ID=31496742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YUP-2005/0084A RS20050084A (en) | 2002-07-31 | 2003-07-22 | Vegfr-2 and vegfr-3 inhibitory anthranylamidopyrydines |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1594841A1 (en) |
JP (2) | JP4777648B2 (en) |
KR (1) | KR20050026535A (en) |
CN (1) | CN1671666A (en) |
AU (1) | AU2003281855A1 (en) |
BR (1) | BR0313122A (en) |
CA (1) | CA2493026C (en) |
CO (1) | CO5720998A2 (en) |
CR (1) | CR7673A (en) |
EC (1) | ECSP055631A (en) |
HR (1) | HRP20050187A2 (en) |
IL (1) | IL166377A0 (en) |
MX (1) | MXPA04012948A (en) |
NO (1) | NO20051035L (en) |
PL (1) | PL374610A1 (en) |
RS (1) | RS20050084A (en) |
RU (1) | RU2005105683A (en) |
WO (1) | WO2004013102A1 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
JP4613157B2 (en) | 2003-01-14 | 2011-01-12 | サイトキネティクス・インコーポレーテッド | Compounds, compositions and methods |
DE102004009238A1 (en) * | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | New aryl amide compounds are kinase inhibitors useful for the treatment and/or prophylaxis of e.g. tumors, psoriasis, rheumatoid arthritis, contact dermatitis, inflammations, endometriosis, scar and benign prostatic hyperplasia |
PL1765327T3 (en) | 2004-06-17 | 2015-01-30 | Cytokinetics Inc | Compounds, compositions and methods |
US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
KR20060071812A (en) * | 2004-12-22 | 2006-06-27 | 주식회사 엘지생명과학 | Novel 3-(2-amino-6-pyridinyl)-4-hydroxyphenyl amine derivatives |
WO2006070878A1 (en) * | 2004-12-28 | 2006-07-06 | Astellas Pharma Inc. | Carboxylic acid derivative or salt thereof |
US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
WO2007070683A2 (en) | 2005-12-15 | 2007-06-21 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
US7989455B2 (en) | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
EP1975166A1 (en) * | 2007-03-30 | 2008-10-01 | Bayer Schering Pharma AG | Synthesis of anthranilamides |
EP2008658A1 (en) * | 2007-06-28 | 2008-12-31 | Bayer Schering Pharma Aktiengesellschaft | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives |
SG192439A1 (en) | 2008-06-27 | 2013-08-30 | Novartis Ag | Organic compounds |
ES2445517T3 (en) * | 2008-08-27 | 2014-03-03 | Leo Pharma A/S | Pyridine derivatives as inhibitors of VEGFR-2 receptor and protein tyrosine kinase |
CN101676267B (en) | 2008-09-16 | 2012-12-26 | 江苏恒瑞医药股份有限公司 | N-4-(1-cyan cyclopentyl) phenyl-2-(4-picolyl) amidogen-3-pyridinecarboxamide salt |
US8389862B2 (en) | 2008-10-07 | 2013-03-05 | Mc10, Inc. | Extremely stretchable electronics |
US9289132B2 (en) | 2008-10-07 | 2016-03-22 | Mc10, Inc. | Catheter balloon having stretchable integrated circuitry and sensor array |
US8372726B2 (en) | 2008-10-07 | 2013-02-12 | Mc10, Inc. | Methods and applications of non-planar imaging arrays |
US8886334B2 (en) | 2008-10-07 | 2014-11-11 | Mc10, Inc. | Systems, methods, and devices using stretchable or flexible electronics for medical applications |
US8097926B2 (en) | 2008-10-07 | 2012-01-17 | Mc10, Inc. | Systems, methods, and devices having stretchable integrated circuitry for sensing and delivering therapy |
US9723122B2 (en) | 2009-10-01 | 2017-08-01 | Mc10, Inc. | Protective cases with integrated electronics |
KR102000302B1 (en) | 2011-05-27 | 2019-07-15 | 엠씨10, 인크 | Electronic, optical and/or mechanical apparatus and systems and methods for fabricating same |
US9171794B2 (en) | 2012-10-09 | 2015-10-27 | Mc10, Inc. | Embedding thin chips in polymer |
CN104086484B (en) * | 2014-07-08 | 2016-05-25 | 上海宣创生物科技有限公司 | Mesylate solvate crystal of nicotinamide derivative and its preparation method and application |
CN105541708A (en) * | 2014-10-28 | 2016-05-04 | 华东理工常熟研究院有限公司 | New crystal form of apatinib sulfate |
CN105622499A (en) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | New crystal of apatinib sulfate |
CN105622498A (en) * | 2014-10-28 | 2016-06-01 | 华东理工常熟研究院有限公司 | New crystal of apatinib sulfate |
JO3705B1 (en) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments |
UA124237C2 (en) * | 2016-06-01 | 2021-08-11 | Байєр Енімал Хелс Гмбх | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
CN106496107A (en) * | 2016-08-31 | 2017-03-15 | 浙江永宁药业股份有限公司 | VEGFR inhibitor 2 and preparation method thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
DE10023486C1 (en) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituted anthranilic acid amides and their use as medicines |
DE10023485A1 (en) * | 2000-05-09 | 2001-11-22 | Schering Ag | New 2-((heteroaralkyl)-amino)-benzamide derivatives, are vascular endothelial growth factor (VEGF) receptors, KDR kinase and FLT kinase inhibitors useful for e.g. treating tumors, psoriasis, arthritis or renal diseases |
US6878714B2 (en) * | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
US20030134836A1 (en) * | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
IL158783A0 (en) * | 2001-05-08 | 2004-05-12 | Schering Ag | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
WO2003048081A2 (en) * | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
-
2003
- 2003-07-22 KR KR1020057001611A patent/KR20050026535A/en not_active Application Discontinuation
- 2003-07-22 RS YUP-2005/0084A patent/RS20050084A/en unknown
- 2003-07-22 AU AU2003281855A patent/AU2003281855A1/en not_active Abandoned
- 2003-07-22 CA CA2493026A patent/CA2493026C/en not_active Expired - Fee Related
- 2003-07-22 PL PL03374610A patent/PL374610A1/en not_active Application Discontinuation
- 2003-07-22 CN CNA03818334XA patent/CN1671666A/en active Pending
- 2003-07-22 JP JP2004525272A patent/JP4777648B2/en not_active Expired - Fee Related
- 2003-07-22 MX MXPA04012948A patent/MXPA04012948A/en not_active Application Discontinuation
- 2003-07-22 EP EP03740470A patent/EP1594841A1/en not_active Withdrawn
- 2003-07-22 BR BR0313122-0A patent/BR0313122A/en not_active IP Right Cessation
- 2003-07-22 RU RU2005105683/04A patent/RU2005105683A/en not_active Application Discontinuation
- 2003-07-22 WO PCT/EP2003/007964 patent/WO2004013102A1/en active Application Filing
-
2005
- 2005-01-20 IL IL16637705A patent/IL166377A0/en unknown
- 2005-02-03 CR CR7673A patent/CR7673A/en not_active Application Discontinuation
- 2005-02-24 EC EC2005005631A patent/ECSP055631A/en unknown
- 2005-02-25 CO CO05017954A patent/CO5720998A2/en not_active Application Discontinuation
- 2005-02-25 NO NO20051035A patent/NO20051035L/en not_active Application Discontinuation
- 2005-02-25 HR HR20050187A patent/HRP20050187A2/en not_active Application Discontinuation
-
2010
- 2010-10-15 JP JP2010233026A patent/JP2011026344A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
NO20051035L (en) | 2005-04-29 |
JP4777648B2 (en) | 2011-09-21 |
ECSP055631A (en) | 2005-04-18 |
JP2005538112A (en) | 2005-12-15 |
IL166377A0 (en) | 2006-01-16 |
JP2011026344A (en) | 2011-02-10 |
EP1594841A1 (en) | 2005-11-16 |
MXPA04012948A (en) | 2005-09-12 |
WO2004013102A1 (en) | 2004-02-12 |
CO5720998A2 (en) | 2007-01-31 |
CN1671666A (en) | 2005-09-21 |
BR0313122A (en) | 2005-07-05 |
PL374610A1 (en) | 2005-10-31 |
AU2003281855A1 (en) | 2004-02-23 |
CA2493026A1 (en) | 2004-02-12 |
CR7673A (en) | 2006-05-29 |
CA2493026C (en) | 2011-05-24 |
RU2005105683A (en) | 2006-01-20 |
HRP20050187A2 (en) | 2005-10-31 |
KR20050026535A (en) | 2005-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS20050084A (en) | Vegfr-2 and vegfr-3 inhibitory anthranylamidopyrydines | |
MXPA03010099A (en) | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3. | |
CY1105140T1 (en) | CYANOANTHRANYLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES | |
JP2004528379A5 (en) | ||
CA2586271A1 (en) | Anthranilamide pyridinureas as vascular endothelial growth factor (vegf)receptor kinase inhibitors | |
CA2397633A1 (en) | Corticotropin releasing factor antagonists | |
AU2008286349A1 (en) | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors | |
GEP20022763B (en) | 2-(3,5-Bis-Trifluoromethyl-Phenyl)-N-Methyl-N-(6-Morpholin-4-Yl-4-O-Tolyl-Pyridin-3-Yl)-Isobutyramide, Method for its Production and Medicament Containing the Same for Treatment of the Diseases Caused by NK-1 Receptor | |
NO20090667L (en) | Tartrate salt of (7S) -7 - [(5-fluoro-2-methyl-benzyl) oxy] -2 - [(2R) -2-methylpiperazin-1-yl] -6,7-dihydro-5H-cyclopenta [b ] pyridine | |
EP1807416B1 (en) | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | |
MX2009012126A (en) | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists. | |
MY180138A (en) | 3,4-di-substituted pyridine compound,methods of using and compositions comprising the same | |
TW200500359A (en) | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
AR035877A1 (en) | DERIVATIVES OF N-OXIDE-ANTRANILAMIDE, ITS USE TO PREPARE A MEDICINAL PRODUCT AND THE MEDICINES CONTAINING THEM | |
HUP0400398A2 (en) | 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-n-methyl-isobutyramide | |
NZ524742A (en) | Bridged piperazine derivatives | |
JP2005500354A5 (en) | ||
DK2914590T3 (en) | NEW ROCK INHIBITORS | |
KR100572189B1 (en) | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds | |
CN203970635U (en) | Hip abduction orthoses | |
UY27283A1 (en) | SELECTIVE ANTRANILAMIDOPIRIDINAMIDS AS VEGFR-2 AND VEGFR-3 INHIBITORS | |
CN209847166U (en) | Radial artery monitoring remaining needle fixing device | |
MXPA05006888A (en) | Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists. | |
KR101412794B1 (en) | New compound, the preparation thereof and the pharmaceutical composition comprising the same for anti-angiogenic drug | |
CN205434542U (en) | Portable venous transfusion frame |